Q1 2027 Cipla Ltd Earnings Call Transcript
Key Points
- Cipla Ltd (BOM:500087) achieved its highest ever Q1 revenue with INR7,100 crores, indicating a strong start to the fiscal year.
- The One India business reported a 12% year-over-year growth, driven by strong performance across key therapies.
- Cipla's branded prescription business saw a market-leading growth of 15.4% during the quarter.
- The company launched several new products, including Duolin Synchobreathe and BILAFAV M, enhancing its respiratory and immunology portfolios.
- Cipla maintains a strong position in the US albuterol MDI market with a 21% market share and successfully launched generic Ventolin in the US.
- The EBITDA margin, excluding other income, stood at 16.7%, which is below the company's historical levels.
- Cipla's South Africa business experienced a decline in tender revenue, impacting overall performance in the region.
- The company faced higher than normal inventory write-offs, affecting gross margins.
- There was a 2% year-over-year revenue growth, which was impacted by accounting changes and adjustments.
- The US FDA issued a Form 483 observation at Cipla's InvaGen facility in New York, which could potentially delay upcoming launches.
Good day, and welcome to Cipla Limited Q1 and FY27 earnings conference call. We have with us today Mr. Achin Gupta, MD and Global CEO; Mr. Ashish Adukia, Global CFO; Ms. Diksha Maheshwari, Head of Investor Relations. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Ms. Diksha Maheshwari Head of Investor Relations. Thank you, and over to you, ma'am.
Thank you, [Danish]. Good afternoon, and a very warm welcome to Cipla's Q1 FY27 Earnings Call. I'm Diksha Maheshwari from the Investor Relations team at Cipla. Let me draw your attention to the fact that on this call, our discussion will include certain forward-looking statements, which are predictions, projections, or other estimates about future events. These estimates reflect our management's current expectations of the future performance of the company.
Please note that these estimates involve several risks and uncertainties that could cause our actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
